ImmunoPrecise Antibodies Ltd. Statistics
Share Statistics
ImmunoPrecise Antibodies Ltd. has 31.06M shares outstanding. The number of shares has increased by 6.08% in one year.
| Shares Outstanding | 31.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 6.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.17M |
| Failed to Deliver (FTD) Shares | 356.19K |
| FTD / Avg. Volume | 62.31% |
Short Selling Information
The latest short interest is 666.14K, so 2.39% of the outstanding shares have been sold short.
| Short Interest | 666.14K |
| Short % of Shares Out | 2.39% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 0.73 |
Valuation Ratios
The PE ratio is -1.66 and the forward PE ratio is -2.94.
| PE Ratio | -1.66 |
| Forward PE | -2.94 |
| PS Ratio | 1.84 |
| Forward PS | 0.5 |
| PB Ratio | 1.33 |
| P/FCF Ratio | -8.01 |
| PEG Ratio | n/a |
Enterprise Valuation
ImmunoPrecise Antibodies Ltd. has an Enterprise Value (EV) of 85.64M.
| EV / Earnings | -3.15 |
| EV / Sales | 3.49 |
| EV / EBITDA | -3.73 |
| EV / EBIT | -6.22 |
| EV / FCF | -15.18 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.
| Current Ratio | 1.41 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -724.32 |
Financial Efficiency
Return on equity (ROE) is -0.8% and return on capital (ROIC) is -27.37%.
| Return on Equity (ROE) | -0.8% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -27.37% |
| Revenue Per Employee | 340.53K |
| Profits Per Employee | -377.46K |
| Employee Count | 72 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 5.83 |
Taxes
| Income Tax | -1.53M |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by -71.01% in the last 52 weeks. The beta is 0.27, so ImmunoPrecise Antibodies Ltd.'s price volatility has been higher than the market average.
| Beta | 0.27 |
| 52-Week Price Change | -71.01% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 571.64K |
Income Statement
In the last 12 months, ImmunoPrecise Antibodies Ltd. had revenue of $24.52M and earned -$27.18M in profits. Earnings per share was $-1.06.
| Revenue | 24.52M |
| Gross Profit | 12.05M |
| Operating Income | -13.76M |
| Net Income | -27.18M |
| EBITDA | -22.95M |
| EBIT | -13.76M |
| Earnings Per Share (EPS) | -1.06 |
Balance Sheet
The company has $3.46M in cash and $13.68M in debt, giving a net cash position of -$10.22M.
| Cash & Cash Equivalents | 3.46M |
| Total Debt | 13.68M |
| Net Cash | -10.22M |
| Retained Earnings | -100.27M |
| Total Assets | 59.96M |
| Working Capital | 93.00K |
Cash Flow
In the last 12 months, operating cash flow was -$4.25M and capital expenditures -$1.40M, giving a free cash flow of -$5.64M.
| Operating Cash Flow | -4.25M |
| Capital Expenditures | -1.40M |
| Free Cash Flow | -5.64M |
| FCF Per Share | -0.22 |
Margins
Gross margin is 49.16%, with operating and profit margins of -56.13% and -110.85%.
| Gross Margin | 49.16% |
| Operating Margin | -56.13% |
| Pretax Margin | -117.07% |
| Profit Margin | -110.85% |
| EBITDA Margin | -93.6% |
| EBIT Margin | -56.13% |
| FCF Margin | -23.02% |
Dividends & Yields
IPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -265% |
| FCF Yield | -45.05% |
Analyst Forecast
The average price target for IPA is $5, which is 1150% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 1150% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Nov 23, 2020. It was a backward split with a ratio of 1:5.
| Last Split Date | Nov 23, 2020 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -2.6 |
| Piotroski F-Score | 3 |